STAT+: Pharmalittle: We’re reading about a Vaxcyte pneumococcal shot, increasing pharma M&A, and more

AI Summary

Vaxcyte said its pneumococcal vaccine met the primary endpoints in a Phase 3 clinical trial. The result could position it to compete with established vaccines from Pfizer and Merck, amid broader growth in pharmaceutical dealmaking.

Vaxcyte said its pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up a competition with Pfizer and Merck